11月8日,荣昌生物盘中股价大涨5.09%,引发了市场的广泛关注。公司股价大涨的主要原因是其旗舰产品泰它西普针对IgA肾病适应症取得重大进展。
据公司公告,泰它西普用于IgA肾病适应症的III期临床试验已完成患者入组,目前正处于用药随访阶段。这是泰它西普获批上市在即的重要一步。泰它西普一旦获批上市用于IgA肾病,将显著扩大公司产品的使用范围,为公司带来新的利润增长点。
分析人士指出,投资者对于泰它西普获批上市用于新适应症的预期升温,成为推动荣昌生物股价大涨的主要驱动力。展望未来,随着泰它西普新适应症审批进程的推进,荣昌生物股价有望持续受到资金青睐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.